We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HSX:LSEHiscox Ltd Analysis

Data as of 2026-03-11 - not real-time

£1,474.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Hiscox Ltd (HSX.L) is trading at 1,474 p, comfortably above its 20‑day SMA (1,475.6) and 50‑day SMA (1,463.8) while staying well above the 200‑day SMA (1,359.6), indicating a sustained bullish trend despite a neutral RSI of 49.3. Fundamentally, the insurer posts a solid 4.7% revenue growth, a healthy operating margin of 22% and a ROE of 15.8%, while its PE of 11.3 is well below the industry average of 17.3, suggesting relative undervaluation. Recent material news – a $300 million share buy‑back and earnings that beat expectations – has already lifted the stock 5.7%, reinforcing investor confidence in capital return and earnings momentum.
The dividend yield of 2.53% with a modest 25% payout ratio, strong cash position (≈£1 bn) versus debt (£0.84 bn), and an upside potential of roughly 8% per the DCF model support a favorable risk‑adjusted profile. However, a 30‑day volatility of 27% and a bearish MACD histogram signal short‑term caution, making the stock attractive for disciplined investors who can tolerate moderate price swings.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Share buy‑back program signaling confidence and potential price support
  • Current price near strong technical support at 1,420 p
  • Increasing volume confirming buying interest

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Stable earnings growth and attractive dividend yield
  • PE advantage versus peers but MACD bearish divergence
  • Potential for earnings acceleration from specialty lines

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued valuation metrics (low PE, DCF upside) and favorable analyst targets
  • Strong balance sheet with low debt‑to‑equity and sustainable dividend policy
  • Resilient business model across diversified insurance segments

Key Metrics & Analysis

Financial Health

Revenue Growth4.70%
Profit Margin15.01%
P/E Ratio11.3
ROE15.82%
ROA4.23%
Debt/Equity21.27
P/B Ratio162.2
Op. Cash Flow£72.8M
Free Cash Flow£2.3B
Industry P/E17.3

Technical Analysis

TrendBullish
RSI49.3
Support£1,420.00
Resistance£1,560.50
MA 20£1,475.60
MA 50£1,463.76
MA 200£1,359.58
MACDBearish
VolumeIncreasing
Fear & Greed Index76.34

Valuation

Fair Value£12,375.42
Target Price£1,591.02
Upside/Downside7.94%
GradeUndervalued
TypeBlend
Dividend Yield2.53%

Risk Assessment

Beta0.26
Volatility27.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.